Traws Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRAW research report →
Range $1 – $1
Price Chart
About the company
Traws Pharma, Inc. , a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19.
- CEO
- Iain D. Dukes
- IPO
- 2013
- Employees
- 7
- HQ
- Newtown, PA, US
Get TickerSpark's AI analysis on TRAW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.69M
- P/E
- -0.71
- Fwd P/E
- 1.94
- PEG
- -0.04
- P/S
- 0.00
- P/B
- -1.94
- EV/EBITDA
- -0.13
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 177.47%
- ROIC
- 497.55%
Latest fiscal year · YoY change
- Revenue
- $2.79M+1134.5%
- Gross Profit
- $2.79M+1203.7%
- Op Income
- $-17,875,000
- Net Income
- $9.17M+116.8%
- EPS
- $0.83+102.4%
- OCF Growth
- +39.0%
- FCF Growth
- +30.3%
- 52W High
- $3.23
- 52W Low
- $0.17
- 50D MA
- $0.40
- 200D MA
- $1.02
- Beta
- 1.53
- RSI (14)
- 28
- Avg Volume
- 607.51K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Traws used a $60 million financing to fund its flu program into 2027, but the FDA placed the U.S. IND on clinical hold, making the U.K. challenge study and regulatory progress the key near-term catalysts.· April 15, 2026
- $60 million private financing was announced, with $10 million upfront and milestone-based warrants tied to MHRA approval, challenge-trial data, and shareholder approval.
- The FDA placed the IND for tivoxavir marboxil on clinical hold due to concerns with the toxicology data package; management is working to resolve it and aims for U.S. advancement in late 2026.
- Management remains optimistic about starting the U.K. seasonal flu challenge study this summer, pending MHRA review, and says a bridging study in Australia is underway to support the package.
- Traws believes tivoxavir could be a once-monthly oral prophylactic for influenza, with broad activity across influenza A and B and potential use in pandemic preparedness stockpiles.
- Year-end 2025 results showed sharply improved reported net income, driven by one-time revenue recognition and the absence of prior-year acquired R&D expense.
For the year ended December 31, 2025, revenue was $2.8 million versus $226,000 in 2024, with the increase mainly from $2.7 million of deferred revenue recognized in Q2 after termination of a legacy oncology licensing agreement. Acquired in-process R&D expense was $0 versus $117.5 million in 2024. R&D expense was $12.1 million versus $12.8 million, and G&A was $8.5 million versus $12.3 million. Net income was $9.2 million, or $0.83 per basic share and $0.82 per diluted share, versus a net loss of $166.5 million, or $(35.21) per basic and diluted share, in 2024. Cash, cash equivalents and short-term investments were approximately $3.8 million at December 31, 2025, versus $21.3 million a year earlier. Management said the new financing plus milestone warrants, if fully exercised, should fund planned expenses into Q1 2027.
Iain Dukes framed the year as substantial progress toward developing tivoxavir marboxil as a next-generation influenza antiviral and said the company is prioritizing it as a once-monthly prophylactic. He emphasized preclinical breadth, bird-flu protection data, and Phase I exposure lasting more than 3 weeks, and said the new tablet formulation showed a 30% increase in exposure in preclinical studies. His tone was constructive but cautious: he highlighted optimism around MHRA review, the Australia bridging study, and the summer challenge trial, while acknowledging the FDA clinical hold and saying the U.S. path depends on resolving toxicology concerns.
Charles Parker focused on the financing structure and runway. He said the private placement provides up to $60 million in potential gross proceeds, including $10 million upfront, a $10 million Series A warrant upon MHRA approval for the challenge trial, a $10 million Series B warrant after shareholder approval and challenge-trial data, and a Series C warrant that could add $30 million over 3 years, with an accelerated exercise feature if the stock trades at 2x the $1.67 deal price for 30 consecutive days. He also outlined the 2025 financials: cash of about $3.8 million at year-end, revenue of $2.8 million, R&D of $12.1 million, G&A of $8.5 million, and net income of $9.2 million.
Analysts pressed on the FDA clinical hold, asking what new experiments might be needed and whether immunogenicity is a risk given similarity to Xofluza; management said it will repeat some assays, add new assays, and use Xofluza as a control, arguing there is no reason tivoxavir should differ materially. On the U.K. side, management said MHRA is on a 30-day review clock and that different regulators can reach different conclusions from the same toxicology package, pointing to prior approval in Australia as evidence of potential progress. A final question focused on whether dosing could be more frequent than once monthly; management said it is open to weekly or other dosing if challenge data support it and will assess protection at 1, 2, 3, and 4 weeks before deciding on the best Phase IIb/III strategy.
The positive case is that Traws now has enough capital to push tivoxavir through key near-term milestones, with management saying funding can support planned expenses into Q1 2027. The company also has a clear development thesis: a once-monthly oral flu prophylaxis with broad influenza A/B activity, plus potential bird-flu and stockpile applications, and it expects to get readouts from the Australia bridging study and U.K. challenge trial.
The biggest risk is regulatory: the FDA has already put the IND on clinical hold over toxicology concerns, and there is no guarantee the issue will be resolved quickly or without additional work. The MHRA review is still pending, so the summer start for the challenge trial is not assured, and management also signaled that the optimal dosing frequency may not be once monthly, which could complicate the product positioning if the data point to a different regimen.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 70.7%
- Shares Outstanding
- 15.37M
- Float Shares
- 10.86M
of shares held by institutions
34 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Orbimed Advisors LLC | 1.20M | 0 |
| Ally Bridge Group (Ny) LLC | 786.24K | 0 |
| Adage Capital Partners Gp, L.L.C. | 730.00K | 0 |
| Adar1 Capital Management, LLC | 597.73K | 0 |
| Lynx1 Capital Management LP | 559.47K | 0 |
| Ikarian Capital, LLC | 478.14K | 0 |
| Sphera Funds Management Ltd. | 398.49K | 0 |
| Citadel Advisors LLC | 205.68K | ▲ 205.68K |
| Alyeska Investment Group, L.P. | 164.38K | 0 |
| Vanguard Capital Management LLC | 152.85K | ▼ 177.20K |
| Boothbay Fund Management, LLC | 133.94K | 0 |
| Geode Capital Management, LLC | 110.97K | ▼ 395 |
Held by 16 ETFs
Biggest fund positions in TRAW by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 9, 26 | Pauza Charles David | other | 97,000 |
| Jul 9, 26 | CAUTREELS WERNER | other | 14,150 |
| Jul 9, 26 | Savchuk Nikolay | other | 93,000 |
| Jul 9, 26 | STOVER JACK E | other | 14,150 |
| Jul 9, 26 | Dukes Iain D. | other | 274,000 |
| Jul 9, 26 | Redfield Robert | other | 84,000 |
| Jul 9, 26 | Parker Charles Nolan | other | 90,000 |
| Jul 9, 26 | Shoemaker Mary Teresa | other | 14,150 |
| Jul 9, 26 | Clarke Trafford | other | 14,150 |
| Jul 9, 26 | Leaman John Harold | other | 14,150 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRAW coverage
Recent articles, reports, and earnings notes.
No research on TRAW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRAW report →Traws Pharma Reports Third Quarter 2026 Financial Results and Provides Business Highlights
globenewswire.com · Nov 16
Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones
benzinga.com · Nov 12
Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID®
globenewswire.com · Nov 12
Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW)
defenseworld.net · Sep 29
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
globenewswire.com · Aug 14
Traws Pharma (NASDAQ:TRAW) Shares Up 4.8% – Here’s What Happened
defenseworld.net · Aug 4
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
globenewswire.com · Jun 22
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study
benzinga.com · Jun 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.